Cardium Reports on First Quarter 2008 Highlights and Financi...(y of risks and uncertainties many of whi...)

Date:5/9/2008

y of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, and our ability to obtain necessary funding, regulatory approvals and expected qualifications, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such devices and launch new devices will be successful or completed within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Excha
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results